Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Henlius Biotech Prices Hong Kong IPO to Raise $477 Million

publication date: Sep 11, 2019

Shanghai Henlius Biotech announced it would price its Hong Kong IPO to raise as much as $477 million, valuing the company at up to $3.5 billion. Henlius, which was formed as a JV between Fosun Pharma and US-based Henlius, is the biologic arm of Fosun, which owns 60% of the company. It is developing a portfolio of biosimilars, bio-betters and innovative biologics. In February, Henlius was approved to market a biosimilar to Roche's Rituxan, a treatment for lymphoma. It is the first approval for Henlius and the first biosimilar approved in China. More details....

Stock Symbol: (HK: 02196: SHA: 600196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China